SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy?

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Hank who wrote (6199)2/16/1999 2:58:00 PM
From: Bob Trocchi  Read Replies (2) of 7041
 
Hank...

>>Beautiful. Sounds like they didn't sell a single pill of Vasoscam in the fourth quarter<<

Come on now Hank, read the whole story correctly. It clearly states that they had royalty revenue of $163K for 1998 from Vasomax in Mexico. Now $160k is a $652k run rate for a full year. Lets give some growth and figure it is a $1M yearly run rate. Not bad for a company that reports losing $6.0M in this Q!!

Zona's biggest claim to fame is that they have a cash balance of $51M ( that was in the PR)and that alone can carry them for a couple of years even if they never sell Vasomax or get US FDA approval. They sure may not have sold a lot of Vasomax but they have sure sold a lot of hype and have been very successful in getting investors to depart with their money!

Bob T. (currently short)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext